Madhur Nayan1, Filipe L F Carvalho1, Adam S Feldman2. 1. Department of Urology, Massachusetts General Hospital, 55 Fruit St, GRB 1100, Boston, MA, 02114, USA. 2. Department of Urology, Massachusetts General Hospital, 55 Fruit St, GRB 1100, Boston, MA, 02114, USA. afeldman@mgh.harvard.edu.
Abstract
INTRODUCTION: Active surveillance (AS) is an established approach in the management of low-risk, localized prostate cancer. While the use of AS to manage intermediate-risk (IR) disease has gradually increased over time, there remains uncertainty with regards to its safety, with only a minority of IR patients currently being managed with this approach. MATERIALS AND METHODS: We conducted a narrative review based on an analysis of the literature focusing on articles describing AS for IR prostate cancer. We focus on the uncertainty surrounding AS in IR disease by discussing variations in the definitions and guideline recommendations associated with IR disease, and describing the limitations of the evidence from observational studies and randomized trials. CONCLUSION: The safety of AS for IR disease remains unknown, given the lack of randomized trials and the limitations of the current observational studies. Further research is needed to identify select patients with IR prostate cancer that can be managed safely with AS.
INTRODUCTION: Active surveillance (AS) is an established approach in the management of low-risk, localized prostate cancer. While the use of AS to manage intermediate-risk (IR) disease has gradually increased over time, there remains uncertainty with regards to its safety, with only a minority of IR patients currently being managed with this approach. MATERIALS AND METHODS: We conducted a narrative review based on an analysis of the literature focusing on articles describing AS for IR prostate cancer. We focus on the uncertainty surrounding AS in IR disease by discussing variations in the definitions and guideline recommendations associated with IR disease, and describing the limitations of the evidence from observational studies and randomized trials. CONCLUSION: The safety of AS for IR disease remains unknown, given the lack of randomized trials and the limitations of the current observational studies. Further research is needed to identify select patients with IR prostate cancer that can be managed safely with AS.
Authors: Anna Bill-Axelson; Lars Holmberg; Hans Garmo; Kimmo Taari; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Ove Andrén; Gunnar Steineck; Hans-Olov Adami; Jan-Erik Johansson Journal: N Engl J Med Date: 2018-12-13 Impact factor: 91.245
Authors: Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal Journal: N Engl J Med Date: 2016-09-14 Impact factor: 91.245
Authors: Katherine O Castle; Karen E Hoffman; Lawrence B Levy; Andrew K Lee; Seungtaek Choi; Quynh N Nguyen; Steven J Frank; Thomas J Pugh; Sean E McGuire; Deborah A Kuban Journal: Int J Radiat Oncol Biol Phys Date: 2012-07-24 Impact factor: 7.038
Authors: Nicolas Mottet; Roderick C N van den Bergh; Erik Briers; Thomas Van den Broeck; Marcus G Cumberbatch; Maria De Santis; Stefano Fanti; Nicola Fossati; Giorgio Gandaglia; Silke Gillessen; Nikos Grivas; Jeremy Grummet; Ann M Henry; Theodorus H van der Kwast; Thomas B Lam; Michael Lardas; Matthew Liew; Malcolm D Mason; Lisa Moris; Daniela E Oprea-Lager; Henk G van der Poel; Olivier Rouvière; Ivo G Schoots; Derya Tilki; Thomas Wiegel; Peter-Paul M Willemse; Philip Cornford Journal: Eur Urol Date: 2020-11-07 Impact factor: 20.096
Authors: Timothy J Wilt; Tien N Vo; Lisa Langsetmo; Philipp Dahm; Thomas Wheeler; William J Aronson; Matthew R Cooperberg; Brent C Taylor; Michael K Brawer Journal: Eur Urol Date: 2020-02-21 Impact factor: 20.096
Authors: Richard J Bryant; Jon Oxley; Grace J Young; Janet A Lane; Chris Metcalfe; Michael Davis; Emma L Turner; Richard M Martin; John R Goepel; Murali Varma; David F Griffiths; Ken Grigor; Nick Mayer; Anne Y Warren; Selina Bhattarai; John Dormer; Malcolm Mason; John Staffurth; Eleanor Walsh; Derek J Rosario; James W F Catto; David E Neal; Jenny L Donovan; Freddie C Hamdy Journal: BJU Int Date: 2020-02-12 Impact factor: 5.588